|
Jenex Gains European Approval to Market
Jenex Gains European Approval to Market
interceptCS
August 2, 2007
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), announced today they have received CE Mark approval for their revolutionary interceptCS Cold Sore Prevention System. This approval permits the Company to begin marketing interceptCS in European Union (EU) countries and other countries around the world that recognize the CE Mark approval process.
“We are very pleased to have received CE approval to market interceptCS”, says Michael Jenkins, President and CEO of The Jenex Corporation. “The CE Mark will allow Jenex the opportunity to access European markets, and other international jurisdictions, with our revolutionary product for the prevention of cold sores. This is a significant milestone and the first step towards commercializing interceptCS in other major world markets.”
It is estimated that there are between 45 million and 90 million recurrent cold sore sufferers in the European community.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology. Patents in the United States, Canada, Australia and Europe protect the technology. interceptCS is the first product proven and approved to prevent cold sores. More information about interceptCS can be found at www.interceptCS.com
Forward Looking Statements
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
For more information please contact:
The Jenex Corporation
207 – 940 Sheldon Court
Burlington, Ontario
L7L 5K6
Michael A. Jenkins, President
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
|
